|
Investors | |
|
Success of the pharmaceutical and biotechnology industry is ultimately dependent on getting drug candidates developed and approved for clinical use. Increasingly, cancer has become a main therapeutic focus as a result of continued and growing cancer patient’s need for better therapeutics. Supratek recognizes this reality, and has pursued a product driven business strategy to find new ways of helping patients by developing novel therapeutics against difficult to treat cancers. This approach has attracted investors that are sophisticated in the health care sector. Supratek’s main investors include: | |
| Malmsten Invest AB | A private investment company founded in 1986 focused mainly on investing in life sciences enterprises in Europe, the United States and Canada. The Malmsten family is one of the former major founding shareholders of Pharmacia AB, which merged with Pfizer Inc. in 2003. |
| Dynamic Funds | Dynamic Funds is a leading Canadian investment firm offering a comprehensive line-up of investment products and services designed to meet the financial needs of clients. Their products and services cover a wide breadth of financial management and investment solutions and span every major sector and geographic region. |
| MVI Medinvest Ltd. | MVI Medinvest Ltd. is a privately held investment company with primary focus on the biotechnology sector. For its investment activity, MVI Medinvest is advised by senior executives with experience in the international pharmaceutical and investment industries. |
| Thominvest Group | Thominvest is a leading private investment group based in Finland with international interests. Group businesses comprise equity holdings and alternative investments, such as hedge funds, real estate, private equity and venture capital. |
| Celox S.A. | Celox is focuses primarily on long term investments in small to medium size companies in diversified geographic areas and sectors. It has a flexible investment strategy allowing investment in companies in different stages of development. |
|
If you would like more information about Supratek Pharma, we welcome your inquiries. Prospective and existing investors may contact Karen Dianne Berg at karen.berg@supratek.com or (514) 849-6094 ext. 207. | |
